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older nursing home residents
Tadeja Gracner1* , Patricia W. Stone2, Mansi Agarwal3, Mark Sorbero4, Susan L Mitchell5,6 and Andrew W. Dick7

Abstract
Background: Though work has been done studying nursing home (NH) residents with either advanced Alzheimer’s
disease (AD) or Alzheimer’s disease related dementia (ADRD), none have distinguished between them; even though
their clinical features affecting survival are different. In this study, we compared mortality risk factors and survival
between NH residents with advanced AD and those with advanced ADRD.
Methods: This is a retrospective observational study, in which we examined a sample of 34,493 U.S. NH residents
aged 65 and over in the Minimum Data Set (2011–2013). Incident assessment of advanced disease was defined as
the first MDS assessment with severe cognitive impairment (Cognitive Functional Score equals to 4) and diagnoses
of AD or ADRD. Demographics, functional limitations, and comorbidities were evaluated as mortality risk factors
using Cox models. Survival was characterized with Kaplan-Maier functions.
Results: Of those with advanced cognitive impairment, 35 % had AD and 65 % ADRD. At the incident assessment
of advanced disease, those with AD had better health compared to those with ADRD. Mortality risk factors were
similar between groups (shortness of breath, difficulties eating, substantial weight-loss, diabetes mellitus, heart
failure, chronic obstructive pulmonary disease, and pneumonia; all p < 0.01). However, stroke and difficulty with
transfer (for women) were significant mortality risk factors only for those with advanced AD. Urinary tract infection,
and hypertension (for women) only were mortality risk factors for those with advanced ADRD. Median survival was
significantly shorter for the advanced ADRD group (194 days) compared to the advanced AD group (300 days).
Conclusions: There were distinct mortality and survival patterns of NH residents with advanced AD and ADRD. This
may help with care planning decisions regarding therapeutic and palliative care.
Keywords: Advanced cognitive impairment, End-of-Life, Alzheimer’s disease, Dementia, Survival

Background
Alzheimer’s disease (AD) and related dementias (ADRD)
are the 6th leading cause of death in the United States
(US) [1–3]. Unless another fatal illness intervenes, these
diagnoses will progress to an advanced stage, ultimately
resulting in death [4]. Approximately 70 % of persons
with AD or ADRD die in nursing homes (NHs) [5]. Accurately identifying a health state we refer to as advanced disease is therefore critical to providing optimal
* Correspondence: tgracner@rand.org
1
RAND Corporation, 1776 Main Street, Santa Monica, CA 90401, USA
Full list of author information is available at the end of the article

care; as is differentiating mortality risk factors and survival patterns across groups because underlying causes
of decline are heterogeneous.
Although AD is the most recognized form of dementia, its clinical features and cognitive impairments affecting survival are different from ADRD, which includes
dementia with Lewy bodies (DLB), frontotemporal dementia, Parkinson’s, mixed dementia, as well as vascular
or multi-infarct dementia [6–8]. Researchers have found
that ADRD patients have shorter survival compared to
those with AD [9–11], that their survival depends on
sex, cognitive level, neuropathology [2, 3, 12–14], and
that AD and ADRD patients differ in their co-existing
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functional impairments or co-morbidities [10, 15, 16].
For instance, eating difficulties and related weight-loss
are common complications in patients with AD, and are
a significant predictor of end of life [14, 17]. On the
other hand, for patients with ADRD such as DLB, walking and fall-related injuries are among the largest mortality risks [18, 19], whereas these risks are not as
substantial for patients with AD. For some other types
of ADRD, such as vascular dementia, hypertension, diabetes, and stroke remain the most important mortality
risk factors [20, 21]. Finally, evidence shows that disease
progression is more rapid for those with ADRD than for
patients with AD [22, 23].
However, the previous work studying AD and especially
ADRD does not focus on its most severe and advanced
stage. Though work has been done studying survival and
mortality risks in people with either advanced AD or
ADRD [3, 11–13, 18, 19, 24], less is known about whether
residents with advanced AD differ from those with advanced ADRD in their mortality risk factors and survival
patterns [14, 25, 26]. Lack of prognosticators across AD
and ADRD may thus fail to recognize dementia as a terminal illness for these patients.
Early identification of when NH residents with either
AD or ADRD enter the stage of advanced cognitive impairment may improve end of life care. Though previous
researchers have used the routinely collected Minimum
Data Set (MDS) to identify residents with advanced cognitive impairment [27], none have distinguished between
AD and ADRD [28]. Using routine MDS assessments,
our goal was to identify incident advanced cognitive impairment as observed in MDS and evaluate the differences in survival and mortality risk factors for those
with advanced AD and those with advanced ADRD.

Methods
This is a retrospective cohort study of a nationally representative sample of US NH residents with advanced AD
or ADRD between 2011 and 2013. The Institutional Review Boards approved this study.
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Study population and measures

We started with a random sample of 1 million NH residents aged 65 and above who had at least one quarterly or
annual assessment from 2011 to 2013. From these, we
identified residents for whom we observed the incident
advance cognitive impairment assessment in MDS, defined as the first assessment on which the criteria were
satisfied, with at least one prior quarterly, annual, or admission assessment in which they were not satisfied.
These criteria required a diagnosis of AD (MDS item
I4200) and/or a diagnosis of ADRD. For ADRD, we use
the MDS item I4800, which refers to Non-Alzheimer’s dementia, including DLB, frontotemporal dementia, Parkinson’s or Creutzfeldt-Jakob disease, mixed dementia, or
vascular or multi-infarct dementia. In addition, a cognitive
function score (CFS) equal to 4 (i.e., severely impaired)
had to be present on the same assessment [29, 30]. We
did not use ICD9 for any diagnoses. How CFS is obtained
has been explained elsewhere [30].
In our data, most of the NH residents who were diagnosed with dementia had only ADRD diagnoses (65 %),
but a significant fraction had both ADRD and AD diagnoses (21 %), and only 14 % had AD diagoses only. To
explore how different or similar their survival patterns
were, we estimated survival and hazard functions for
each of these three mutually exclusive groups. Residents
with AD and those with AD and ADRD exhibited similar survival patterns, but different patterns from those
who were diagnosed only with ADRD (see the Supplement, eFigure 1). Guided by these empirical patterns, we
divided our sample into two mutually exclusive groups:
those with AD (with or without an ADRD diagnosis)
and those with ADRD (without an AD diagnosis), hereafter referred to as AD and ADRD, respectively. Like
others, we assumed that AD and ADRD were considered
permanent once diagnosed [14, 29]. To protect against
data errors and false positives, we required advanced
cognitive impairment to be present on at least two
assessments unless there were only two or fewer assessments remaining before death (in which case we required only one positive assessment).

Data source

We used data from the 2011 to 2013 MDS 3.0, which is
a comprehensive, standardized resident screening and
assessment tool, federally mandated for use in all licensed US NHs. We included the routine assessments
for NH residents that are required upon admission (or
readmission), quarterly thereafter, and at any time there
is a significant change in health status. We also included
assessments that are completed at or around 5, 14, 30,
60, and 90 days following admission or readmission from
hospital. We obtained Vital Status data linked to individual MDS identifiers, providing date of death for each
NH resident through November 2016.

Predictors of survival

Based on the literature, demographics, functional status,
comorbidities, and other health conditions were selected
a priori as potential predictors of survival [2, 10, 14–16,
18, 19, 26, 31–33]. Residents’ demographic characteristics included age (60–74, 75–84, 85–94, and 95+), sex,
marital status (yes/no), and race/ethnicity (American
Indian or Alaskan, Asian, African American, Hispanic,
Native Hawaiian/Pacific Islander, Caucasian). Functional
status was measured using Activities of Daily Living
(ADL) items: eating, bathing, locomotion, bed mobility,
walking, toileting, transferring, hygiene, or dressing. A
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score ≥ 3 indicated difficulty with the ADL. Comorbidities at the advanced cognitive impairment incident assessment included indicators for diabetes mellitus,
congestive heart failure, hypertension, chronic obstructive pulmonary disease (COPD), and stroke, as well as depression. Other health conditions included bowel or
urinary incontinence (rarely or never vs. occasionally,
frequently, or always), experiencing shortness of breath
sitting or lying, pneumonia or other respiratory tract infection, urinary tract infection (UTI) in the previous 30
days, hip fracture in the prior 180 days, and weight-loss
of more than 5 % in the last month or more than 10 % in
the last 6 months.
Statistical analysis

Descriptive analyses were conducted to identify differences in the predictors of survival between AD and
ADRD residents with advanced cognitive illness using
two-sided t-tests. For NH residents whose death date we
observed in the follow-up period, survival was defined as
the duration between their incident advanced disease assessment and date of death. Residents that survived until
the end of the follow-up period were treated as censored. We estimated Cox multivariable survival models
with nonparametric baseline survival functions stratified
by sex for both AD and ADRD residents. We specified
the models conditional on the predictor variables listed
above and measured on the assessment identifying incident advanced cognitive impairment, as well as interactions between AD and ADRD and selected predictors.
We assessed the proportional hazards assumption by
examining log-log survival plots. Kaplan-Maier survival
functions were developed separately by AD and ADRD
as well as by sex. We calculated 25th, 50th and 75th percentiles in survival time (days) along with the probability
of survival at the end of year 1, 2 and 3 since the onset
of advanced cognitive impairment, both in total and by
sex. All statistical analyses were performed using
STATA MP, version 16 [34].

Results
There were 34,493 (3.5 %) residents that met eligibility
criteria for advanced cognitive impairment; among
those, 35.0 % had AD and 65.0 % had ADRD. Most of
the NH residents in our sample (i.e., with incident advanced cognitive impairment) died before the end of
follow-up with only 11.9 % of the survival times
censored.
Table 1 presents the comparison of AD and ADRD
groups. About 65 % percent were female, and about 80 %
were white non-Hispanic. All differences reported below
are statistically significant at p < 0.01. At the onset of advanced cognitive impairment, NH residents diagnosed
with ADRD had more comorbidities than those with
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AD, such as diabetes mellitus (28.88 and 24.28 %, respectively), stroke (21.57 and 12.48 %, respectively), and
hypertension (74.83 and 71.12 %, respectively). NH residents with ADRD were also more likely to experience
difficulties with ADLs, such as eating (66.35 and 63.76 %,
respectively), walking (88.32 and 82.22 %, respectively),
and locomotion (86.34 and 79.67 %, respectively), and to
have experienced heart failure (19.44 and 15.16 %, respectively) and shortness of breath in the 7 days since
the last MDS assessment (11.83 and 8.16 %, respectively).
However, residents with ADRD were less likely than
those with AD to experience depressive symptoms
(41.52 and 45.64 %, respectively).
Table 2 presents the Cox survival regressions. Most
predictors of death had similar hazard ratios (HR) for
both AD and ADRD. In both AD and ADRD residents
with advanced cognitive impairment, the following comorbidities were associated with greater mortality risk:
diabetes mellitus (HR 1.11 and 1.12, respectively), heart
failure (HR 1.24 and 1.26, respectively) and COPD (HR
1.13 for both). Mortality risks in AD and ADRD residents with advanced cognitive illness were highest for
those who were experiencing shortness of breath (HR
1.65 and 1.54, respectively), substantial weight-loss (HR
1.31 and 1.35, respectively) or difficulty eating (HR 1.28
and 1.31, respectively) and pneumonia (HR 1.34 and
1.22, respectively). Difficulty with walking and bed mobility were both significant mortality risk factors for
ADRD residents (HR 1.14 (p < 0.01) and 1.90 (p < 0.05),
respectively) only. Experiencing stroke and difficulty
with locomotion were both significant mortality risk factors for AD residents (HR 1.08 (p < 0.05) for both).
Among the predictors, only having a stroke and being
older than 95 years were significantly different between
AD and ADRD residents.
There were differences in mortality risk factors for
both AD and ADRD within sex (see Table 3). The largest mortality risk factors for women regardless of AD
or ADRD diagnoses were shortness of breath, heart failure, difficulty eating, and weight-loss (HR 1.70, 1.26,
1.26, 1.31 for ACI-AD and HR 1.51, 1.27, 1.34 and 1.34,
for ACI-ADRD; all p < 0.01). Stroke and difficulty with
transfer were also significant mortality risk factors for
women with AD (HR 1.16 and 1.20, respectively, both
p < 0.01). Difficulty with walking (HR 1.17, p = 0.01),
hypertension and urinary incontinence (HR 1.06 and
1.12, respectively, both p < 0.05) were significant mortality risk factors for women with ADRD. For men, diabetes mellitus, heart failure, difficulties with bed mobility
or eating, and substantial weight-loss were significant
risk factors regardless for both AD and ADRD residents
(HR 1.10, 1.19, 1.37, 1.33, 1.21, 1.48, and 1.28, respectively, for AD; HR 1.12, 1.26, 1.31, 1.16, 1.16, 1.55, and
1.33, respectively for ADRD, all p < 0.05); and COPD
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Table 1 Descriptive Statistics of NH residents with advanced cognitive impairment at the incident assessment
AD (N = 12,093)

ADRD (N = 22,400)

Difference

Mean (%)

(95% CI)

Mean (%)

(95% CI)

p-value

Age: 65-74

10.51

(9.96, 11.06)

11.60

(11.18, 12.02)

-0.01**

Age: 75-84

38.34

(37.47, 39.2)

33.36

(32.74, 33.98)

0.05**

Age: 85-94

45.55

(44.66, 46.43)

46.38

(45.72, 47.03)

-0.01

Age: 95+

5.61

(5.2, 6.02)

8.66

(8.29, 9.03)

-0.03**

Married

36.01

(35.14, 36.87)

30.77

(30.16, 31.38)

0.05**

Caucasian

81.55

(80.86, 82.24)

77.42

(76.88, 77.97)

0.04**

Am. Ind. or Alaskan

0.20

(0.12, 0.28)

0.29

(0.22, 0.36)

-0.00

Asian

1.27

(1.07, 1.47)

2.16

(1.97, 2.35)

-0.01**

Socio-demographics

African American

9.76

(9.23, 10.29)

12.65

(12.21, 13.08)

-0.03**

Hispanic

5.56

(5.15, 5.97)

5.27

(4.97, 5.56)

0.00

Native Haw./Pac.Isl.

0.21

(0.13, 0.29)

0.39

(0.31, 0.47)

-0.00**

Comorbidities
Type 2 Diabetes

24.28

(23.52, 25.05)

28.88

(28.29, 29.48)

-0.05**

Stroke

12.48

(11.89, 13.07)

21.57

(21.03, 22.11)

-0.09**

Hypertension

71.12

(70.32, 71.93)

74.83

(74.26, 75.4)

-0.04**

Depression

45.64

(44.75, 46.53)

41.52

(40.88, 42.17)

0.04**

Heart Failure

15.16

(14.52, 15.8)

19.44

(18.92, 19.96)

-0.04**

COPD

13.69

(13.07, 14.3)

16.80

(16.31, 17.29)

-0.03**

Walking

82.22

(81.54, 82.9)

88.32

(87.9, 88.74)

-0.06**

Eating

63.76

(62.91, 64.62)

66.35

(65.73, 66.97)

-0.03**

Functional Status (ADL 3+)
Difficulties with…

Bed mobility

86.58

(85.98, 87.19)

90.67

(90.29, 91.05)

-0.04**

Transfer

87.06

(86.46, 87.65)

91.67

(91.30, 92.03)

-0.05**

Locomotion

79.67

(78.96, 80.39)

86.34

(85.89, 86.79)

-0.07**

Dressing

94.07

(93.65, 94.49)

95.20

(94.92, 95.48)

-0.01**

Toilet

94.07

(93.65, 94.49)

95.65

(95.38, 95.91)

-0.02**

Hygiene

93.48

(93.04, 93.92)

94.48

(94.18, 94.78)

-0.01**

Bowel incontinence

87.68

(87.09, 88.27)

88.85

(88.43, 89.26)

-0.01**

Urinary incontinence

95.12

(94.71, 95.52)

95.22

(94.92, 95.53)

-0.00

Shortness of breath

8.16

(7.67, 8.65)

11.83

(11.4, 12.25)

-0.04**

Pneumonia

7.03

(6.57, 7.49)

9.00

(8.62, 9.37)

-0.02**

Urinary tract infect.

17.05

(16.38, 17.72)

19.45

(18.93, 19.97)

-0.02**

Other Conditions

Hip fracture

6.29

(5.86, 6.73)

5.93

(5.62, 6.24)

0.00

Weight loss

17.38

(16.71, 18.06)

18.39

(17.89, 18.9)

-0.01*

Note: Mean and standard deviation reported for a list of covariates at the time of the incident advanced cognitive impairment assessment. *, and **, describe
statistically significant difference between means at a p-value smaller or equal to 0.05 and 0.01, respectively, computed by conducting a two-sided equality of
means t-test between advanced AD and ADRD groups
Abbreviations: AD Alzheimer’s disease, ADRD related dementias, ADL activities of daily living, COPD chronic obstructive pulmonary disease, NH nursing home
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Table 2 Mortality risk factor estimates using cox regression
models for NH residents with advanced cognitive impairment
All (N = 29,058)
AD Mean (95 % CI)

ADRD Mean (95 % CI)

Age: 75–84

1.326** (1.229–1.432)

1.258** (1.186–1.335)

Age: 85–94

1.705** (1.579–1.841)

1.578** (1.488–1.674)

Age: 95+

2.158** (1.931–2.413)

1.840** (1.702–1.988)

Married (= 1)

1.135** (1.084–1.189)

1.128** (1.088–1.170)

Am. Ind. or Alaskan

1.278 (0.961–1.699)

0.900 (0.640–1.266)

Asian

0.746** (0.614–0.906)

0.608** (0.541–0.683)

African American

0.789** (0.731–0.852)

0.762** (0.722–0.804)

Hispanic

0.698** (0.631–0.772)

0.679** (0.629–0.732)

Native Haw./Pac.Isl

0.83 (0.567–1.216)

0.752* (0.571–0.990)

Type 2 Diabetes

1.107** (1.051–1.167)

1.122** (1.081–1.164)

Stroke

1.080* (1.012–1.152)

0.974 (0.935–1.014)

Hypertension

1.022 (0.974–1.073)

1.028 (0.990–1.068)

Depression

0.952* (0.912–0.994)

0.960* (0.929–0.992)

Heart Failure

1.240** (1.164–1.322)

1.262** (1.207–1.320)

COPD

1.133** (1.061–1.209)

1.135** (1.082–1.190)

Socio-demographics

Comorbidities

Functional Status (ADL 3+):
Difficulties…
Walking

1.053 (0.970–1.142)

1.143** (1.071–1.221)

Eating

1.277** (1.217–1.341)

1.313** (1.265–1.361)

Bed mobility

1.074 (0.982–1.175)

1.089* (1.005–1.180)

Transfer

1.106 (0.996–1.229)

1.025 (0.932–1.126)

Locomotion

1.086* (1.008–1.169)

1.056 (0.997–1.119)

Dressing

1.02 (0.902–1.153)

1.007 (0.915–1.108)

Toilet

0.97 (0.853–1.103)

1.036 (0.938–1.145)

Hygiene

1.032 (0.923–1.155)

0.988 (0.909–1.073)

Bowel incontinence

1.071 (0.995–1.153)

1.048 (0.990–1.110)

Urinary incontinence

1.046 (0.934–1.172)

1.066 (0.976–1.163)

Shortness of breath

1.651*** (1.484–1.838)

1.539** (1.437–1.648)

Pneumonia

1.289** (1.157–1.437)

1.185** (1.105–1.271)

Urinary Tract Infection

1.024 (0.961–1.091)

1.096** (1.048–1.146)

Hip fracture

0.906* (0.828–0.992)

0.947 (0.882–1.016)

Weight Loss

1.311*** (1.230–1.397)

1.345** (1.285–1.408)

Other conditions

Note: *, and ** denotes coefficient significance at the 0.05, or 0.01 levels,
respectively. Robust standard errors reported in brackets. Weight loss is
recorded if the resident lost > 5 % of his or her weight last month or > 10 % in
6 months
Abbreviations: AD Alzheimer’s disease, ADRD related dementias, ADL activities
of daily living, COPD chronic obstructive pulmonary disease, NH nursing home

was a significant risk factor for men with ADRD (HR
1.10, p < 0.05) but not for men with AD.
As presented in Fig. 1; Table 4, the median survival
times were on average 300 (CI95 % 286 to 315) and 194
(CI95 % 186 to 202) days for AD and ADRD residents,
respectively. By the end of year 1, the probability of survival for NH residents was 46.3 % (CI95 % 45.4 to 47.2),
and 39.0 % (CI95 % 39.4 to 39.7) for those with AD and
ADRD, respectively. Absolute differences in survival
rates between disease groups decreased with time, and
by year 3 the rate of survival for NH residents with AD
was 19.9 % (CI95 % 19.2 to 20.7) compared to 16.6 %
(CI95 % 16.1 to 17.1) for those with ADRD. Men had
substantially lower survival rates than women throughout the first three years regardless of the dementia diagnosis. For instance, by year 3, the survival rate for
women with AD was 23.5 % (CI95 % 22.6 to 24.4) compared to 19.2 % (CI95 % 18.6 to 19.9) for those with
ADRD. For men, the survival rate at year 3 was around
12 % regardless of dementia diagnosis.

Discussion
Significant differences were found in health status at the
incident advanced cognitive impairment, as well as in
survival patterns. We find that among NH residents with
advanced cognitive impairment, on average, those with
ADRD are of worse health compared to those with AD
at their incident assessment of advanced cognitive impairment as observed in MDS. This may be largely because ADRD is a heterogenous collection of conditions
that likely have different underlying causes, comorbidities and the rate of disease progression, but it
may also be that ADRD is diagnosed later in life than
AD, particularly in a NH environment [13, 14, 20, 23].
On average, residents with ADRD are more likely than
those with AD to be older than 85 at the incident advanced cognitive impairment assessment.
On the other hand, most of mortality risk factors were
similar across groups. This highlights an important fact
which is that regardless of the type of dementia, issues
that residents, as well as families and caregivers are confronted with at the end of one’s life are similar. For both,
AD and ADRD residents with advanced cognitive impairment, the largest mortality risk factors were shortness of breath, pneumonia, weight loss and difficulties
with eating; and these were similar for both, men and
women. Stroke and difficulty with locomotion were a
significant risk factor for women with AD only, but difficulty with bed mobility, walking and UTI were significant risk factors for residents with ADRD, regardless of
sex. These results are consistent with the literature. For
instance, eating difficulties and related weight-loss are
common complications in patients with AD, and are a
significant predictor of end of life [14, 17]. On the other
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Table 3 Mortality risk factor estimates using cox regression models for NH residents with advanced cognitive impairment by sex
WOMEN (N = 19,575)

MEN (N = 9,483)

AD Mean (95 % CI)

ADRD Mean (95 % CI)

AD Mean (95 % CI)

ADRD Mean (95 % CI)

Age: 75–84

1.270** (1.147–1.406)

1.296** (1.192–1.409)

1.447** (1.288–1.627)

1.290** (1.184–1.406)

Age: 85–94

1.667** (1.507–1.843)

1.644** (1.514–1.784)

1.885** (1.668–2.129)

1.675** (1.533–1.831)

Age: 95+

2.170** (1.900–2.478)

1.966** (1.782–2.170)

2.486** (1.931–3.202)

1.994** (1.723–2.308)

Married (= 1)

0.999 (0.938–1.064)

0.976 (0.927–1.028)

0.981 (0.907–1.061)

1.042 (0.985–1.103)

Am. Ind. or Alaskan

1.525** (1.155–2.013)

1.082 (0.688–1.700)

0.89 (0.472–1.678)

0.654 (0.388–1.103)

Asian

0.82 (0.637–1.055)

0.642** (0.559–0.738)

0.601** (0.442–0.818)

0.550** (0.445–0.679)

African American

0.802** (0.728–0.882)

0.731** (0.682–0.783)

0.716** (0.627–0.816)

0.781** (0.717–0.851)

Hispanic

0.719** (0.633–0.816)

0.641** (0.579–0.709)

0.626** (0.530–0.739)

0.699** (0.624–0.784)

Native Haw./Pac.Isl

0.822 (0.540–1.252)

0.721 (0.518–1.004)

0.862 (0.370–2.006)

0.738 (0.455–1.197)

Socio-demographics

Chronic conditions
Type 2 Diabetes

1.070* (1.001–1.144)

1.103** (1.053–1.156)

1.102* (1.013–1.200)

1.124** (1.055–1.197)

Stroke

1.159** (1.070–1.255)

0.984 (0.936–1.035)

0.916 (0.819–1.025)

0.932** (0.871–0.998)

Hypertension

1.037 (0.977–1.101)

1.060* (1.011–1.113)

1.013 (0.933–1.101)

0.998 (0.938–1.063)

Depression

0.974 (0.924–1.027)

0.991 (0.952–1.032)

0.968 (0.898–1.044)

0.950 (0.897–1.006)

Heart Failure

1.257** (1.164–1.358)

1.267** (1.199–1.337)

1.189** (1.062–1.332)

1.255** (1.160–1.359)

COPD

1.124** (1.035–1.220)

1.129** (1.064–1.199)

1.090 (0.977–1.216)

1.097* (1.016–1.185)

Walking

1.073 (0.971–1.186)

1.169** (1.077–1.269)

1.036 (0.902–1.189)

1.093 (0.984–1.214)

Eating

1.260** (1.188–1.338)

1.340** (1.281–1.402)

1.370** (1.259–1.491)

1.314** (1.234–1.399)

Bed mobility

0.974 (0.872–1.087)

1.073 (0.971–1.186)

1.331** (1.139–1.557)

1.163* (1.020–1.327)

Transfer

1.199** (1.051–1.367)

1.01 (0.897–1.137)

0.922 (0.768–1.107)

1.032 (0.884–1.205)

Functional status (ADL 3+)
Difficulties…

Locomotion

1.092 (0.997–1.195)

1.091* (1.017–1.172)

1.123 (0.987–1.278)

1.031 (0.937–1.134)

Dressing

0.981 (0.848–1.134)

1.015 (0.903–1.141)

1.082 (0.847–1.382)

1.004 (0.850–1.185)

Toilet

0.958 (0.822–1.116)

1.031 (0.910–1.167)

0.931 (0.725–1.196)

1.046 (0.887–1.233)

Hygiene

1.073 (0.937–1.230)

0.948 (0.857–1.049)

0.929 (0.757–1.140)

1.026 (0.887–1.187)

Bowel incontinence

1.078 (0.986–1.179)

1.009 (0.941–1.082)

1.005 (0.886–1.141)

1.089 (0.986–1.202)

Urinary incontinence

1.062 (0.926–1.217)

1.121* (1.007–1.248)

1.132 (0.917–1.397)

0.986 (0.850–1.145)

Shortness of breath

1.699** (1.480–1.949)

1.509** (1.382–1.647)

1.481** (1.245–1.762)

1.553** (1.392–1.732)

Pneumonia

1.259** (1.088–1.457)

1.108* (1.006–1.221)

1.210* (1.027–1.426)

1.163** (1.052–1.285)

Urinary Tract Infection

1.051 (0.977–1.131)

1.119** (1.062–1.179)

1.1 (0.965–1.254)

1.170** (1.071–1.277)

Other conditions

Hip fracture

0.961 (0.864–1.068)

0.945 (0.870–1.026)

0.797* (0.665–0.956)

1.034 (0.901–1.187)

Weight Loss

1.313** (1.216–1.417)

1.340** (1.268–1.416)

1.281** (1.143–1.437)

1.331** (1.227–1.444)

Note: *, and ** denotes coefficient significance at the 0.05, or 0.01 levels, respectively. Robust standard errors reported in brackets. Weight loss is recorded if the
resident lost > 5 % of his or her weight last month or > 10 % in 6 months
Abbreviations: AD Alzheimer’s disease, ADRD related dementias, ADL activities of daily living, COPD chronic obstructive pulmonary disease, NH nursing home

hand, for patients with ADRD such as DLB, walking and
fall-related injuries were among the largest mortality
risks, possibly because these patients displayed severe
deficits in attention and visuospatial processing, whereas
these were not as a substantial risk factors for patients
with AD. Patients with Parkinson’s disease, for instance,

have been found to have increased risk for UTI due to
voiding dysfunctions, but also more commonly experienced swallowing disorders leading to eating difficulties
and significant weight-loss. An important difference that
we identified between AD and ADRD with advanced disease compared to the existing evidence is that stroke
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Fig. 1 Survival functions of nursing home residents with advanced cognitive impairment by diagnosis type and sex. Note: Author’s estimation of
the Kaplan-Meier survivor function. Abbreviations: AD, Alzheimer’s disease; ADRD, related dementias; F, female; M, male

was mainly a significant risk factor for residents with
AD, especially women, and not for those with ADRD.
Other evidence shows that for some other types of
ADRD, such as vascular for dementia, hypertension, diabetes, and stroke remain the most important mortality
risk factors [20, 35].
We also observe that mortality risk was consistently
higher for whites (vs. non-whites) among residents

diagnosed with either advanced AD or ADRD. Consistent with prior work, these results could be driven by a
sample selection due to lower institutionalization rates
among non-white residents with AD or ADRD [36].
Thus, non-white residents in our sample may have been
wealthier and/or of better health than the white NH residents or average non-whites in community who we do
not observe. There may be several unobserved mediators

Table 4 Survival probability and time since incident advanced cognitive impairment and death
Survival time in days (CI 95 %)

Probability of survival (%)

N

25 % (CI 95 %)

50 % (CI 95 %)

75 % (CI 95 %)

Year 1 (CI 95 %)

Year 2 (CI 95 %)

Year 3 (CI 95 %)

AD

11,978

57 (54, 62)

300 (286, 315)

891 (856, 920)

46.3 (45.4, 47.2)

29.6 (28.8, 30.5)

20.0 (19.2, 20.7)

Women

8,087

74 (67, 78)

374 (352, 395)

1031 (996, 1069)

50.4 (49.3, 51.5)

33.4 (32.4, 34.4)

23.5 (22.6, 24.4)

Men

3,891

38 (35, 43)

192 (177, 209)

623 (583, 661)

38.0 (36.4, 39.5)

21.8 (20.5, 23.1)

12.6 (11.6, 13.7)

ADRD

22,045

35 (33, 36)

194 (186, 202)

731 (712, 752)

39.0 (39.4, 39.7)

25.0 (24.4, 25.6)

16.6 (16.1, 17.1)

Women

14,296

41 (39, 44)

246 (233, 260)

845 (820, 871)

43.0 (42.2, 43.8)

28.4 (27.6, 29.1)

19.2 (18.6, 19.9)

Men

7,749

27 (25, 29)

132 (124, 140)

517 (494, 550)

31.7 (30.7, 32.7)

18.8 (18.0, 19.7)

11.7 (11.0, 12.5)

Note: 25th, 50th, and 75th percentile of survival times is obtained from S(t), the Kaplan-Meier estimate of the survivor function in Fig. 1. Survival time is reported
in days. We report 95 % confidence intervals in the brackets
Abbreviations: AD Alzheimer’s disease, ADRD related dementias, CI confidence interval
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in our data that could explain the differences in mortality risk, such as genetics, residents’ socio-economic status, available resources, social networks, and social
capital, as well as unobserved psychological stressors,
discrimination, or access to medical or home or other
care [37, 38].
Our results regarding survival are also supported by
published literature. Researchers focusing on severe dementia (either AD or ADRD) have found that the median
survival ranges from 2 days to 16 months but variability in
survival time estimates is high [29, 31, 32]. Our survival
rate estimates are similar to those found by Mitchell et al.
2010, who found that about 40 % of patients with advanced dementia (either AD or ADRD) die within 1 year
[29]. We add to this evidence by showing that there are
differences in expected survival for those with AD compared to those with ADRD as identified in MDS, particularly in the first year after their onset of advanced
cognitive impairment in which those with ADRD have
higher mortality rates. Specifically, our estimated survival
rate at year 1 is 46.3 % for AD and 39 % for ADRD residents (with 65 % having ADRD). Like us, other investigators have found that the risk of mortality is smaller for
patients with AD than for those with the ADRD but these
studies have typically not limited their focus to those with
advanced cognitive impairment and did not use MDS to
differentiate the groups [11, 33]. As others, we find lower
survivals for men in both groups [11, 21, 29].
This study has limitations. First, diagnostics of the advanced cognitive impairment may be imprecise or under
reported, particularly given the difficulty in diagnosing AD
and ADRD. Though some of the advanced cognitive impairment cases may be missed [39], MDS data includes
strict protocols about data reporting as well as the timing
of assessments, and MDS 3.0 in particular has shown either excellent or very good reliability in assessments, their
clinical relevance, and low rates of missing responses [40];
largely addressing concerns that the diagnoses are misclassified. Many have used similar measures to ours to identify
cognitive impairments [14, 27, 29, 41, 42]. Second, ADRD
arises from a variety of heterogeneous conditions, only
some of which are identifiable (and imperfectly at that) in
the MDS data. The extent to which each of those conditions gives rise to different patterns of survival in our data
remains unknown, but the heterogeneity of ADRD may
explain the different patterns of survival between AD and
ADRD. Additionally, we cannot identify residents with a
specific condition (e.g., DLB only) or exclude those usually
not included in the ADRD definition (e.g., CreutzfeldtJakob disease). Third, an important goal of this paper was
to define measures of advanced cognitive impairment that
would be highly predictive of mortality, and although a
large fraction of those identified with advanced disease
died relatively quickly, the survival functions still have a
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long tail. Fourth, whether the first observed incident of advanced cognitive impairment in MDS is the actual time
advanced disease is identified is unknown yet unavoidable
due to data limitations. Because advanced cognitive impairment definitions require assessment data (complete
with data on physical and cognitive limitations) we can
only identify the first time the cognitive decline is observed in MDS for those who resided in NH before the
disease progressed to advanced illness. As a result, we
could identify the entire period of advanced cognitive impairment for only a fraction of those who reside in NH.
Though other clinical data may provide a more precise
measure of the advanced cognitive impairment onset, our
study utilizes MDS, which is a relatively easily accessible
data source for other researchers. Since our focus is end
of life, identifying the incident advanced cognitive impairment diagnosis as observed in the MDS is informative in
that it provides a conservative estimate of survival for
people with advanced disease once admitted to NH. Finally, though we studied mortality risk factors, our data
did not allow us to investigate pathways or mediators giving rise to these factors, such as genetics, residents’ socioeconomic status, resources, social network or ties, as well
as psychological stressors, discrimination, access to care
or idiosyncratic behaviors [37, 38]. These questions are
important to address in future research.

Conclusions
This study provided new evidence showing that routine
MDS assessments may be used to differentiate between
mortality risks and survival between AD and ADRD
overall and by sex. Though mortality risks for NH residents with advanced ADRD and AD were largely similar,
those with ADRD had worse health status on average
and shorted survival from their observed incident of advanced cognitive impairment. Findings may inform future developments of risk tools used to identify end of
life among AD and ADRD residents and help inform
care planning decisions regarding therapeutic and palliative care.
Abbreviations
AD: Alzheimer’s disease; ADL: activities of daily living; ADRD: Alzheimer’s
related dementia; CFS: Cognitive function score; COPD: Chronic obstructive
pulmonary disease; MDS: Minimum Data Set; NH: Nursing home; UTI: Urinary
tract infections
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